Q-omics provides the consensus-scored PDE5A profile across patient tissues and cancer cell-line models. PDE5A expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PDE5A is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, PDE5A protein abundance shows 29,239 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, BLCA, and PDAC as cancer lineages where PDE5A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDE5A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDE5A survival associations across molecular data types. PDE5A RNA expression shows survival associations in the most cancer types (28), followed by mutation status (7) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDE5A RNA expression–survival associations across cancer types. High PDE5A expression shows unfavorable associations in UVM, BLCA and KIRP, but favorable associations in KIRC, BRCA and THCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PDE5A RNA expression.
This table summarizes PDE5A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 9. The strongest signals are observed in BLCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PDE5A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDE5A shows lower tumor expression in BLCA, COAD, LUSC, READ and LUAD and higher tumor expression in THCA. The BLCA box plot shows higher PDE5A RNA expression in normal versus tumor tissue (log2 FC = −2.760, t-test p < 0.001).
This table shows molecular features associated with PDE5A in patient tissues and cancer cell lines. In patient samples, PDE5A shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, PDE5A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
